about
Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen.MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression.A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.ABC transporters as mediators of drug resistance and contributors to cancer cell biology.High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4).Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis.Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo.MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin.Too many targets, not enough patients: rethinking neuroblastoma clinical trials.Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastomaDrugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding InterfaceInhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastomaTargeting Functional Activity of AKT Has Efficacy against Aggressive NeuroblastomaMRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cellsCCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growthAccelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapyMouse models of high-risk neuroblastoma
P50
Q35477568-0A8ADA9B-BC59-459F-9A2C-1FDFEFE04229Q36021061-577794F8-5E15-42F0-899F-A68F24E165AEQ36962372-C96B83D9-48AF-4E3A-B8CA-B92DB1F42F33Q38727375-94CD0A65-0A44-458B-9127-F24B54E6A4DAQ38834784-B6B93C16-6799-41EE-882A-1D24E3C225FEQ38980150-A64D7E7C-7AE0-4D3C-B1B2-A3BAAAA1535AQ42282862-00A5CA7B-46FA-4725-9897-6280E4022364Q48714552-14D51C09-9B02-4C20-860B-52B130CBFD04Q52309585-2A1D260A-BEDB-4BE9-96F0-6C69CE101733Q52597787-180356FF-C881-444C-812C-19F0C9968AB2Q89840105-79D88456-BA88-4805-B064-7D6FD7E6EDEEQ90000953-1BB5CC1E-3163-4200-B10A-F2B8548CF3EFQ91283008-4206AC0D-9F15-47DB-871B-5AD97FA71B85Q91659139-C3BEB962-BE5C-4951-AB9B-1460CEF2DDC5Q91852784-3E61AC9D-84CA-4289-8AC0-CCD8E8BB8191Q92160034-D9C146FF-B065-4D99-B282-9E4F0DDD1E5AQ92527643-2AF4CDD1-8A01-4CF7-B595-41CE5AAE35F7Q92986764-29653C58-F5A7-4013-AF05-DA56AB6ED193
P50
description
investigador
@es
researcher
@en
name
Jamie Fletcher
@en
type
label
Jamie Fletcher
@en
prefLabel
Jamie Fletcher
@en
P31
P496
0000-0003-2949-9469